Articles Published in 2011

Actavis expands to Latin America

Friday, October 7, 2011 11:49 AM

Actavis Group CEO Claudio Albrecht has reported a major sales expansion into Latin America, among the world's fastest-growing markets for generic drugs.

More... »

Birch joins Truveris

Friday, October 7, 2011 11:11 AM

Truveris has named Bryan Birch chairman, president and CEO.

More... »

US Army to host pharma industry day for potential contractors

Thursday, October 6, 2011 02:33 PM

The United States Army will be hosting an industry day in the Hyatt hotel in Newport RI, on October 14, 2011. The purpose of the industry day is to inform pharmaceutical contractors about the BSCAV/Nerve Agent prophylactic contract is to select, develop, and manufacture an FDA-approved drug/biologic to increase survival and decrease incapacitation such that forces can maintain operational effectiveness within acontaminated area following nerve agent exposure, irrespective of nerve agent type. The BSCAV project is indented to provide medical countermeasures against the effects of organophosphorous nerve agent chemical warfare threats. The proponent for this effort is The Medical Identification and Treatment Systems (MITS) Joint Product management office of The Chemical Biological Medical Systems (CBMS) Joint Project management office of the Joint Program executive office for chemical and biological defense (JPEO-CBD).

More... »

Aptiv Solutions acquires SRA Global Clinical Development

Thursday, October 6, 2011 01:08 PM

Reston, Va.-based Aptiv Solutions, which designs and executes adaptive clinical trials and medical device studies, has acquired SRA Global Clinical Development (GCD), the CRO division of SRA International, based in Durham, N.C., with offices in Paris, France and Milton Park, England.

More... »

Puma Biotech, Pfizer ink licensing agreement for Nertatinib

Thursday, October 6, 2011 01:01 PM

Puma Biotechnology, has signed an agreement with Pfizer to license the worldwide commercial rights to neratinib, a potent, irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases.  Neratinib is being studied in the neoadjuvant, adjuvant and metastatic settings in patients with HER2/ErbB2 positive breast cancer.

More... »

FDA commissioner outlines steps to spur biomedical innovation

Thursday, October 6, 2011 12:18 PM

FDA Commissioner Margaret A. Hamburg, M.D., has released a blueprint containing immediate steps that can be taken to drive biomedical innovation, while improving the health of Americans.

More... »

Report: U.S. medical innovation at risk without funding

Thursday, October 6, 2011 12:03 PM

U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investment away from the United States towards Europe and Asia, according to a report by the National Venture Capital Association'sMedIC Coalition.

More... »

GSK seeks $2 billion acquisition in India

Thursday, October 6, 2011 11:58 AM

GlaxoSmithKline is eyeing acquisitions worth as much as $2 billion in India in an effort to cement its position in one of the world's fastest-growing drug markets, the group's chief executive told U.K. newspaper The Times in an interview, according to Dow Jones Newswires.

More... »

Almac, Greenphire collaborate in direct patient payment services

Thursday, October 6, 2011 11:39 AM

The Almac Group and Greenphire have reported that Almac’s Clinical Technologies business unit, the provider of IXRS (Interactive Voice and Web Response) services relating to patient and drug supply management, has formed an exclusive alliance with Greenphire to offer joint services relating to patient payment administration for clinical trials. This new service improves current methods of manual patient payment management and alleviates administrative burden on personnel in biopharmaceutical companies and contract research organizations, allowing them to focus on more study-specific responsibilities.

More... »

DATATRAK inks multi-year agreement with specialty biotech company

Thursday, October 6, 2011 10:58 AM

DATATRAK International, a technology and services company focused on global eClinical solutions for the clinical trials industry, has signed a multi-year enterprise agreement with a specialty biologics and vaccines company.  Recognizing the value of enterprise engagements, the specialty biotech will utilize the DATATRAK ONE unified software suite to conduct a series of trials.

More... »